Despite the failure of antiangiogenic therapies at improving overall survival in MPM, the high expression of VEGFR2 on mesothelioma cells helps the tyrosine kinase inhibitor therapies to remain an attractive option for future research, particularly when combined with PD-1/PDL-blocking agents as is occurring in new ongoing clinical trials. The gene discussed is KDR; the disease is mesothelioma.